Virtually every corner of the stock market has had a bad 2022, including initial public offerings. The Renaissance IPO ETF (IPO), which tracks the performance of new public companies, fell 57% in 2022, recording the biggest single-year decline on record. That comes just two years after the biggest annual increase ever. Renaissance data shows that total proceeds from new companies going public fell by more than $7 billion in 2022, reaching the lowest level since at least 2013. Despite a slow year for With the IPOs, analysts predict some stocks that start trading in 2022 will have big profits. CNBC Pro looked at 2022 IPOs for companies tracked by at least seven analysts, with an average price target implying a gain of at least 15%. Of those, more than 60% of analysts have a buy rating on them. Among the shortlisted names is Mobileye Global, a company specializing in autonomous driving technology and assistance. The stock is up more than 66% since its market debut in October. Mobileye is covered by 14 analysts, and about two-thirds of them rate the stock as a buy. On average, analysts see the stock up about 20% over the next 12 months. “We hope Mobileye will repeat its success in ADAS [advanced driver assistance systems] JPMorgan analyst Samik Chatterjee, who rated the stock as overweight. [cooperative perception on vehicles] led by the adoption of Advanced ADAS, in conjunction with Supervisors, Drivers and [mobility as a service] platform, which will allow ADAS to scale to [autonomous vehicles]driving a revenue CAGR of 38% between 2022 and 2030, which translates to a revenue of $23 billion after this decade,” the analyst wrote.Eye-care maker Bausch + Lomb also made the list. This stock, with 66% of analysts rating it a buy, is set to rise 25% next year Bausch + Lomb has fallen 13% since going public in May. Other stocks made the list. This book is CinCor Pharma, Corebridge Financial and Credo Technology.